Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …
standard first-line treatment for most patients with hormone receptor (HR) positive, human …
APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential
K Butler, AR Banday - Journal of Hematology & Oncology, 2023 - Springer
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine
deaminases involved in innate and adaptive immunity. However, some APOBEC family …
deaminases involved in innate and adaptive immunity. However, some APOBEC family …
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …
[HTML][HTML] APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and …
Background: The APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like) family-mediated mutagenesis is widespread in human cancers. However, our …
like) family-mediated mutagenesis is widespread in human cancers. However, our …
APOBEC3: friend or foe in human papillomavirus infection and oncogenesis?
Human papillomavirus (HPV) infection is a causative agent of multiple human cancers,
including cervical and head and neck cancers. In these HPV-positive tumors, somatic …
including cervical and head and neck cancers. In these HPV-positive tumors, somatic …
Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies
Breast cancer remains the most frequently diagnosed cancer in women worldwide. Delayed
presentation of the disease, late stage at diagnosis, limited therapeutic options, metastasis …
presentation of the disease, late stage at diagnosis, limited therapeutic options, metastasis …
The effects of clonal heterogeneity on cancer immunosurveillance
Intratumor heterogeneity (ITH) is associated with tumor progression in several clinical and
experimental settings and contributes to therapeutic resistance. Its relation to cancer …
experimental settings and contributes to therapeutic resistance. Its relation to cancer …
APOBEC alteration contributes to tumor growth and immune escape in pan-cancer
H Guo, L Zhu, L Huang, Z Sun, H Zhang, B Nong… - Cancers, 2022 - mdpi.com
Simple Summary The APOBEC3 family (apolipoprotein B mRNA editing enzyme catalytic
polypeptide-like) was shown to induce tumor mutations through an aberrant DNA editing …
polypeptide-like) was shown to induce tumor mutations through an aberrant DNA editing …
Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types from 10,983 cancer patients
Whole genome sequencing (WGS) allows exploration of the complete compendium of
oncogenic processes generating characteristic patterns of mutations. Mutational signatures …
oncogenic processes generating characteristic patterns of mutations. Mutational signatures …
APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR/Chk1 inhibitors
C Zong, Z Zhang, L Gao, J He, Y Wang, Q Li… - Cell Death & …, 2023 - nature.com
The cytidine deaminase, Apolipoprotein B mRNA editing enzyme catalytic subunit 3B
(APOBEC3B, herein termed A3B), is a critical mutation driver that induces genomic …
(APOBEC3B, herein termed A3B), is a critical mutation driver that induces genomic …